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Abstract
Background:  We describe a simple approach we used to identify barriers and tailor an
intervention to improve pharmacological management of hypertension and hypercholesterolaemia.
We also report the results of a post hoc exercise and survey we carried out to evaluate our
approach for identifying barriers and tailoring interventions.
Methods: We used structured reflection, searched for other relevant trials, surveyed general
practitioners and talked with physicians during pilot testing of the intervention. The post hoc
exercise was carried out as focus groups of international researchers in the field of quality
improvement in health care. The post hoc survey was done by telephone interviews with physicians
allocated to the experimental group of a randomised trial of our multifaceted intervention.
Results: A wide range of barriers was identified and several interventions were suggested through
structured reflection. The survey led to some adjustments. Studying other trials and pilot testing
did not lead to changes in the design of the intervention. Neither the post hoc focus groups nor
the post hoc survey revealed important barriers or interventions that we had not considered or
included in our tailored intervention.
Conclusions: A simple approach to identifying barriers to change appears to have been adequate
and efficient. However, we do not know for certain what we would have gained by using more
comprehensive methods and we do not know whether the resulting intervention would have been
more effective if we had used other methods. The effectiveness of our multifaceted intervention is
under evaluation in a randomised controlled trial.
Background
Much research has been carried out with the aim of influ-
encing the performance of clinicians. The results have var-
ied [1,2]. As with any human behaviour, clinical practice
is difficult to change. Some strategies that have been eval-
uated, like passive dissemination of clinical practice
guidelines, have had little or no effect on practice [3]. Oth-
ers, like educational outreach visits ("academic detail-
ing") and multifaceted interventions, may be more
effective than passive interventions [1].
The reasons why clinical practice sometimes is not con-
sistent with current best evidence varies across clinical
problems and from one clinician to another. A logical
consequence of this is to tailor quality improvement strat-
egies to address specific barriers [4]. Several trials of
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tailored interventions have been conducted. The methods
used for identifying barriers to change have varied and
there is limited evidence of the relative usefulness of dif-
ferent approaches. However, the choice of method for
identifying barriers has implications, particularly with
regards to resources, since some methods are time con-
suming and demand the involvement of many individu-
als. This represents a practical and financial constraint. On
the other hand, if such approaches lead to the identifica-
tion of important barriers that otherwise would have been
overlooked, they may be worth the effort.
In this article we describe a simple approach we have used
to identify barriers to changing professional practice. This
was done as the first step in a process of developing an
intervention to improve the pharmacological manage-
ment of hypertension and hypercholesterolaemia [5]. The
intervention focused on three specific recommendations
in clinical practice guidelines for hypertension and hyper-
cholesterolaemia [6-8] based on evidence of a gap
between the recommendations and current practice in
Norway:
• Contrary to recommendations, physicians seem to rarely
estimate the risk of cardiovascular disease before initiating
treatment [9]
• Sales of thiazides are low, despite these drugs being rec-
ommended as first-line medication [10]
• Relatively few patients reach recommended treatment
goals [11,12]
We also report the results of a post hoc exercise and a sur-
vey we carried out to evaluate our approach to identifying
barriers and interventions.
Methods
We developed the intervention through a process of iden-
tifying barriers to implementation of recommendations
and measures specifically addressing these barriers ("tai-
loring"). The methods we used were structured reflection,
searching for other relevant trials targeted at improving
the management of hypertension or hypercholesterolae-
mia, conducting a survey among general practitioners and
discussion with physicians during pilot testing of the
intervention.
Structured reflection
The three authors reflected over possible barriers based in
part on our own experience as physicians working in pri-
mary care in Norway. We used a worksheet to structure
our reflection (see Additional file 1). The worksheet
included factors that might act as barriers in the practice
environment, the professional environment, and related
to physicians' knowledge, skills and attitudes. One work-
sheet was completed for each targeted behaviour: increas-
ing the use of cardiovascular risk assessment before
initiating treatment for hypertension or hypercholestero-
laemia, increasing the prescribing of thiazides for the
treatment of uncomplicated hypertension, and increasing
the proportion of patients on medication for hyperten-
sion and hypercholesterolaemia that reach recommended
treatment goals. The worksheet was used to facilitate our
group discussion of possible interventions to address the
identified barriers.
Our research group had recently completed a trial of a
strategy for guidelines implementation when we were
planning this study [13]. In that study the multifaceted
intervention consisted of several passive components.
Information and materials were distributed by mail and
to a large degree we relied on the physicians themselves to
make an effort at changing their practice. The observed
changes in practice were small. In another trial we had
found that the use of active sick leave for back patients was
significantly increased through a proactive intervention
compared to a passive one [14]. Based on these experi-
ences our research group decided to test an active strategy
in this study. Therefore we decided to use outreach visits
("academic detailing") prior to considering specific
barriers.
We considered systematic reviews of interventions to
improve professional practice when we designed our strat-
egy [1]. We searched the Cochrane Group of Effective Care
and Organisation of Care http://www.epoc.uottawa.ca
trial register for trials of interventions targeted specifically
at the management of hypertension or elevated choles-
terol in general practice.
Questionnaire to physicians
We surveyed general practitioners about some of the inter-
ventions about which we were uncertain after our struc-
tured reflection. The details of the survey have been
described elsewhere [9]. Briefly, 265 physicians who had
participated in an earlier trial conducted by our research
group [13] were asked to complete a questionnaire as part
of the study-evaluation. We used that opportunity to seek
answers to the following questions:
1. Do physicians assess cardiovascular risk before pre-
scribing antihypertensive or cholesterol-lowering drugs?
2. If not, would physicians be more likely to do so it they
received a fee for this?
3. Do physicians comply with current regulations limiting
the reimbursement of cholesterol-lowering drugs?BMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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The last question was asked for two reasons. Firstly, we
were considering making risk assessment a condition for
reimbursement of the drugs. Secondly, the existing regula-
tions were a possible barrier to adhering to our recom-
mendations because they conflicted with these.
Pilot testing
During pilot testing of the intervention at two practices,
which were selected for convenience, comments from
physicians relevant to possible barriers were noted. We
also informally evaluated each component of the
intervention.
Post hoc focus groups and structured reflection exercise
After we had finished designing the intervention we had
the opportunity of testing our method of structured reflec-
tion at a gathering of international researchers in the
Research Based Education and Quality Improvement
group (ReBEQI) http://www.rebeqi.org, December 2003.
Each participant was asked to complete a worksheet to
identify barriers and possible interventions related to the
low use of thiazides among general practitioners. They
were randomly allocated to four different groups where
they collaborated on completing the worksheet. They
were also asked to grade the importance of each barrier or
intervention as minor, moderate or major. We disre-
garded those rated as minor. We compared the results
from the four groups with the barriers and interventions
we had identified.
Post hoc survey of physicians exposed to the intervention
While conducting the randomised trial to test the effec-
tiveness of our multifaceted intervention we carried out
telephone interviews with physicians allocated to the
experimental group. They were asked if they adhered to
our recommendations and, if not, why. The responses
where noted down during the interviews.
Results
Barriers and interventions
Figure 1 illustrates the timeframe for the methods used to
identify barriers and interventions. Tables 1, 2, 3 give an
overview of the barriers and interventions that we identi-
fied for each clinical problem.
Many of the barriers were related to a lack of knowledge
and could be addressed through educational interven-
tions. The use of educational outreach visits was logical
since we had planned to use an active intervention, based
on our previous experience, and since this type of inter-
vention has consistently lead to improved professional
behaviour in randomised trials [1]. Similarly, based on
previous experience and the capabilities of the software
we hade developed [13], we planned on using an
electronic risk calculator, electronic prescriptions, patient
information materials, and computerised reminders.
Flow chart indicating time frame for methods used to identify barriers and interventions Figure 1
Flow chart indicating time frame for methods used to identify barriers and interventions. * The trial period ended in December 
2003, and data collection and analysis will be completed in September 2004.
 2001  2002  2003 
Methods  used  Apr-Jun Jul-Sep Oct-Dec  Jan-Mar Apr-Jun Jul-Sep Oct-Dec  Jan-Mar Apr-Jun Jul-Sep Oct-Dec 
Identifying barriers and 
interventions 
           
S t r u c t u r e d   r e f l e c t i o n              
L i t e r a t u r e   s e a r c h               
Survey of general 
practitioners 
           
P i l o t   t e s t i n g                
Post hoc evaluation             
Focus group exercise with 
international researchers 
           
Survey of physicians 
participating in trial 
           
    
Start of randomised controlled trial* BMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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Table 1: Barriers to carrying out cardiovascular risk assessment, and possible interventions to address these
Possible barriers Possible interventions
Time-consuming procedure for the physician - Easy-to-use tools (e.g. risk calculator for computer)
- The patients or an assistant could carry out the risk assessment
- Offer economic compensation
Physician has no risk assessment tool at hand - Provide risk assessment tool
The patients are focused on single risk-factors, not the global picture - Patient-information
Physicians are not used to risk estimation, not educated to do this - Educational outreach visit
- Training
Lack of knowledge among physicians of the relevance of global risk 
assessment
- Information/education (outreach visit)
Physicians have more trust in their own clinical judgement than tables or 
charts
- Education (e.g. case discussions during outreach visit)
Differences in opinion among physicians on the importance of treatment 
of hypertension and hypercholesterolaemia
- Use opinion-leaders and convince clinicians of the high degree of 
consensus in clinical guidelines
May be uncomfortable for physicians to discuss risk-factors with patients - Patient-information
- Offer strategies on how to communicate such information with 
patients
Table 2: Barriers to prescribing thiazides for the treatment of hypertension, and possible interventions to address these
Possible barriers Possible interventions
Physicians are neither familiar with the relevant brand-names nor to the 
use and follow-up of these drugs
- Pre-printed prescriptions, also in electronic format
- Patient information
- Support for the clinical follow-up
Few other clinicians use these drugs - Patient information
- Active promotion of thiazides (through educational outreach visits)
- Point out the consensus among guidelines that thiazides are a first-line 
drug
Specialists may be prescribing other drugs - Identify opinion leaders that advocate the use of thiazides
- Look into possible conflicts of interest
Advocacy by pharmaceutical companies - Point attention to the importance of clinically relevant endpoints when 
studies are quoted (during educational outreach visits)
- Review advertisements to identify the main lines of reasoning that are 
being used
Physicians are worried about possible side-effects and lack of anti-
hypertensive effect.
- Educational outreach visits
Thiazides considered old-fashioned - Argue that these drugs have been thoroughly tested over many years 
(during educational outreach visits)
Table 3: Barriers to reaching recommended treatment goals and possible interventions to address them
Possible barriers Possible interventions
Physicians are not accountable to anyone - Feed-back on to what extent treatment goals are reached among his/
her pool of patients (audit)
Physicians are unsure of what treatment goal to use - Give clear treatment goals (during outreach visit)
- Point at the relatively high degree of consensus among guidelines 
(during outreach visit)
Reluctance and unclear strategy among physicians on how to deal with 
insufficient treatment
- Support for decision-making if goal is not reached
Physicians may be underestimating the consequence of under-treatment - Educational outreach visitBMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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The search (July 2001) of the EPOC trial register for ran-
domised trials with the word "hypertension" in any field
yielded 58 references. Most were excluded after reading
the abstracts, leaving eight, for which the full text was
reviewed [15-22]. This did not lead to any changes in our
intervention strategy. A search for randomised trials with
the word "cholesterol" yielded 13 references. The full text
was reviewed for only one of these [23]. This also pro-
vided little further guidance for designing our interven-
tion. The nine trials that we reviewed are summarised in
table 4.
The survey results did not indicate that a fee for estimating
cardiovascular risk before initiating drug therapy would
affect practice [9]. The survey results also indicated that
physicians are largely not affected by conditions for drug
reimbursement [9]. Moreover, there were no mechanisms
in place to enforce such regulations.
We did not identify additional barriers during pilot testing
of the intervention with five physicians in two practices,
but several of those already identified were confirmed,
particularly barriers to prescribing thiazides.
Based on our findings and an assessment of the feasibility
and evidence of effectiveness for various interventions, we
designed a multifaceted intervention. The elements of the
intervention are described in table 5.
Table 4: Studies targeting the management of hypertension and/or hypercholesterolaemia
Study Objective Intervention Comment
Bass 1986 [15] Improve the detection and 
management of hypertension
Medical assistant oversaw screening, 
attended to education, compliance 
and follow-up
We did not consider this to be a 
feasible intervention in our setting
Aucott 1996 [19] Implement guidelines for cost-
effective management of 
hypertension on medication use and 
cost, blood pressure control, and 
other resource use
Intensive guideline-based education 
and supervision (identification of 
clinical champion, faculty education 
and development, assignment of 
PharmD, clinic-based education and 
precepting of clinicians, monthly 
feedback to practice)
Most elements of this multifaceted 
intervention were already included 
in our own. The trial was conducted 
in a general internal medicine 
teaching clinic, which limits the 
relevance to our primary care 
setting
Rossi 1997 [16] Alter prescribing habits for the 
treatment of hypertension
Guideline reminders placed in the 
charts of patients
Computerised reminders were 
already included as part of our 
multifaceted intervention
Goldberg 1998 [17] Increase compliance with national 
guidelines for the primary care of 
hypertension (and depression)
Academic detailing with or without 
continuous quality improvement 
(CQI) teams
Academic detailing (outreach visit) 
was already included as part of our 
multifaceted intervention. The 
study-findings did not support the 
use of CQI teams
Maclure 1998 [18] Increase understanding of the way in 
which dissemination of evidence 
changes medical practice
Media stories, national warning 
letter, teleconference, small group 
workshops, and newsletters
Our outreach visits were planned as 
interactive sessions, thus serving the 
same purpose as small group 
workshops or teleconferences. We 
did not believe that passive 
distribution of material would be 
useful
Hetlevik 1998 [21] Implement clinical guidelines in the 
treatment of hypertension
Computer based clinical decision 
support system, mailed feedback of 
current practice, invitation to 
seminar at conference
Most interventions were already 
included in our multifaceted 
intervention. We did not believe 
that inviting to conference-seminar 
would be useful
van der Weijden 1999 [23] Assess the feasibility and evaluation 
needs of a cholesterol guideline
Group education, desktop 
supportive materials, feedback on 
performance, and face-to-face 
instruction on location
Most interventions were already 
included in our multifaceted 
intervention
Montgomery 2000 [20] Have an effect on absolute 
cardiovascular risk, blood pressure, 
and prescribing of cardiovascular 
drugs
Computer based clinical decision 
support system plus cardiovascular 
risk chart; or cardiovascular risk 
chart alone
Both interventions were already 
included in our multifaceted 
intervention
Demakis 2000 [22] Improve resident physician 
compliance with standards of 
ambulatory care (including 
hypertension)
Computerised reminder system Intervention was already included in 
our multifaceted interventionBMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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We also considered a number of interventions that we
excluded. For example:
• We considered placing computers in waiting rooms so
that patients could assess their cardiovascular risk before
seeing the physician, but concluded this would be costly
and difficult to implement.
• We considered providing pre-printed prescriptions, but
found this would not to be relevant because most physi-
cians use computerised systems for prescribing.
• We considered exposing conflicts of interest among clin-
ical specialists who advocated using other first line drugs
than thiazides, but elected not to do so.
• We considered exposing techniques used in pharmaceu-
tical advertisements, such as using relative risk reductions
rather than absolute risk reductions [24], but concluded
this would have at best a limited impact.
Post hoc focus groups and structured reflection exercise
Nineteen researchers were divided into four groups. All
groups considered advocacy by drug companies to be a
major barrier to change. Routines or habits were also
included as an important barrier by all the groups, as well
as lack of knowledge concerning the effectiveness of thi-
azides, their favourable adverse effects profile, and their
low cost. All the groups also mentioned competing guide-
lines or diverging opinions as part of the problem. Three
of the groups considered local or national opinion leaders
as potential barriers to change. Patients' expectations or
perceived expectations were also mentioned by three of
the groups.
The interventions recommended by the groups to address
the identified barriers are presented in table 6. All the
groups suggested the use of computerised reminders to
address physicians' lack of knowledge or their habits and
routines. All the groups also suggested some form of inter-
active education, mainly as a counter force to promo-
tional activities by the pharmaceutical industry, and
patient information was suggested by three of the groups.
Two suggested training physicians to address patient
expectations. Two groups suggested developing clinical
guidelines and two suggested audit and feedback, but one
group considered this to be of minor importance.
Table 5: The final multifaceted intervention
Educational outreach visit
- Presentation focusing on three main messages:
1. Relevance of risk estimation and how to do it, including strategies on how to communicate information about risk to patients.
2. Information on evidence in support of effect and the unjustified fear of adverse effects regarding thiazides, pointing at the consensus that exists 
among guidelines. Attention also directed to the importance of clinically relevant endpoints when studies are quoted.
3. Clear recommendations justified by referring to high degree of consensus among guidelines.
- Guidelines handed out, directing attention to the authors (opinion leaders)
Audit & feed-back at outreach visit
- To what extent treatment goals are achieved.
- Drug-choice profile on anti hypertensives
- Level of risk among patients on treatment, compared to a sample (men 40–65 years) not on treatment
Computerised reminders
- Risk assessment
- First-choice antihypertensive drugs
- Treatment goals
Risk assessment tools as charts and in electronic format
Patient-information material
- The relationship between single risk factors and global risk
- Thiazides and beta-blockers.
- Treatment goalsBMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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Table 6: Interventions to address identified barriers (main results from post-hoc focus group and structured reflection exercise)
Barrier: Marketing activities by pharmaceutical industry
Importance of barrier* Interventions Importance of interventions*
Group 1 3 - Competing approaches (educational materials; 
interactive educational workshops)
2
Group 2 3 - Outreach visits 3
Group 3 3 - Small group peer comparison 1–2
Group 4 3 - Continuing education system Not graded
Barrier: Routines and habits
Importance of barrier* Interventions Importance of interventions*
Group 1 3 - Computerised reminders 3
- Audit and feedback 2
- Intention plus/trial of behaviour 2
Group 2 2 - Reminder 3
- Direct mail 3
Group 3 2/3 - Audit and feed back with peer comparison 1
Group 4 Not graded - Computerised reminders Not graded
Barrier: Lack of knowledge
Importance of barrier* Interventions Importance of interventions*
Group 1 2 - Educational material/guidelines 2
- Interactive educational meetings 2
Group 2 2 - Information to patients 2
- Local quality circles 2
Group 3 Not graded - Financial incentives 3
- Reminders/Computerised Decisions Support 
Systems
2
Group 4 Not graded - Continuing medical education Not graded
- Computerised reminders
Barrier: Opinion leaders (or specialists) or competing guidelines
Importance of barrier* Interventions Importance of interventions*
Group 1 3 - Develop national guidelines 2
Group 2 3 - Use opinion leaders 3
Group 3 2 - Guidelines shared by primary and specialist 
physicians
1–2
Group 4 Not graded - Not explicitly addressed -
Barrier: Patient expectations
Importance of barrier* Interventions Importance of interventions*
Group 1 2 - Patient materials 3
- Educational meetings for general practitioners 2
Group 2 Not mentioned - None -
Group 3 Not graded - Skills programme training 2
Group 4 Not graded - Information leaflet to patients about options Not graded
*1 = minor, 2 = moderate, 3 = majorBMC Health Services Research 2004, 4:23 http://www.biomedcentral.com/1472-6963/4/23
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Post hoc survey of physicians exposed to the intervention
Among the 195 physicians exposed to the intervention,
149 (76%) were contacted during the trial period and
agreed to answer our questions. No major additional bar-
riers were identified. However, some physicians ques-
tioned whether adhering to the recommendations would
represent a good use of resources, specifically the recom-
mended treatment goals.
Discussion
Addressing barriers to change with tailored interventions
makes sense and there is some empirical support for this
[1]. It is unclear, however, what methods are the most use-
ful for identifying barriers and interventions.
Several qualitative methods can be used to identify barri-
ers, such as interviews, focus groups and observation.
These methods may be valuable, but they are relatively
labour-intensive. We used a simpler approach to identify-
ing barriers to change. Would the use of other methods
have provided us with important additional information?
Pilot testing and discussions with five physicians in two
practices and interviews with 140 participating physicians
did not indicate additional barriers. The post-hoc focus
groups with international experts did not add much with
regards to barriers and interventions. Several of these
groups included "routines and habits" as a potential bar-
rier, which was not explicitly mentioned among the
barriers identified by the investigators. However, all inter-
ventions that were mentioned by more than one of the
groups in the post-hoc focus group exercise were included
in our multifaceted intervention. Our use of computerised
reminders was based on the assumption that this would
help to establish new routines, although we did not record
routines and habits as a barrier when we developed the
intervention.
There are inherent weaknesses in our approach. One is
that the investigators undertaking the structured reflection
were few and we were prejudiced by our own experiences.
The lack of patient involvement is another limitation,
which possibly lead to an under-emphasis of patient-
mediated interventions. A weakness with the group of
international researchers who participated in the post-hoc
focus groups is their lack of familiarity with the Norwe-
gian context.
A number of trials of tailored interventions have been
conducted. The methods used to identify barriers to
change have varied. Some investigators have simply
hosted a meeting [25,26], others have used
questionnaires [23], conducted focus-groups [27-30] or
interviews [31-33], or both [34]. Others have used a com-
bination of several qualitative methods [35-37]. Some
investigators have used identification of barriers as an
intervention in itself [19,38,39]. The methods that were
used have been poorly described in most of these studies.
Conclusions
Our simple approach to identifying barriers to improving
practice appears to have been effective in identifying all of
the important barriers, and it was efficient. However, we
do not know for certain what barriers other methods
would have identified or whether the intervention could
have been more effective, if we had used other methods.
Further work to address these questions is planned,
including direct comparison of alternative methods and
evaluations of theory-based approaches http://
www.rebeqi.org.
The effectiveness of our multifaceted intervention is under
evaluation in a randomised controlled trial.
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